Parameter
| Biomarker | MYC | Full name | MYC proto-oncogene, bHLH transcription factor | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | 49 kDa | Core Functional Dimensions | Diagnosis, prognosis, and therapeutic targets | |
| Disease | Angiosarcoma | Disease Subtypes | / | ||
| Organ | All cells (cell proliferation regulation) | Test Sample / Technology Platform | Organization (NGS, FISH, WES, WGS) | ||
| Pathobiological Mechanisms | Gene amplification or mutation activation promotes cell proliferation, metabolic reprogramming, and angiogenesis | ||||
| Clinical Availability Status | Clinical validation: secondary core subtype diagnosis markers | ||||
| Notes and Dynamics | The amplification rate of secondary AS (radiation/lymphedema related) is up to 100%, and primary AS is rare (7%), which can be used to distinguish AS from benign vascular lesions | ||||